ASX - By Stock
|
OSL |
Re:
Ann: Half Yearly Report and Accounts
|
|
DrDopamine
|
60 |
29K |
3 |
25/03/21 |
25/03/21 |
ASX - By Stock
|
60
|
29K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Half Yearly Report and Accounts
|
|
DrDopamine
|
60 |
29K |
3 |
24/03/21 |
24/03/21 |
ASX - By Stock
|
60
|
29K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil Investor Update
|
|
DrDopamine
|
23 |
12K |
2 |
22/02/21 |
22/02/21 |
ASX - By Stock
|
23
|
12K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil Investor Update
|
|
DrDopamine
|
23 |
12K |
3 |
21/02/21 |
21/02/21 |
ASX - By Stock
|
23
|
12K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
DrDopamine
|
95 |
39K |
6 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
95
|
39K
|
6
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil receives Singapore regulatory approval
|
|
DrDopamine
|
14 |
7.8K |
5 |
01/06/20 |
01/06/20 |
ASX - By Stock
|
14
|
7.8K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
DrDopamine
|
165 |
67K |
2 |
22/04/20 |
22/04/20 |
ASX - By Stock
|
165
|
67K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
DrDopamine
|
165 |
67K |
5 |
21/04/20 |
21/04/20 |
ASX - By Stock
|
165
|
67K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
DrDopamine
|
165 |
67K |
4 |
20/04/20 |
20/04/20 |
ASX - By Stock
|
165
|
67K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
DrDopamine
|
165 |
67K |
3 |
11/04/20 |
11/04/20 |
ASX - By Stock
|
165
|
67K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
DrDopamine
|
165 |
67K |
5 |
06/04/20 |
06/04/20 |
ASX - By Stock
|
165
|
67K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
DrDopamine
|
165 |
67K |
5 |
05/04/20 |
05/04/20 |
ASX - By Stock
|
165
|
67K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
DrDopamine
|
165 |
67K |
8 |
03/04/20 |
03/04/20 |
ASX - By Stock
|
165
|
67K
|
8
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
DrDopamine
|
165 |
67K |
4 |
02/04/20 |
02/04/20 |
ASX - By Stock
|
165
|
67K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
DrDopamine
|
165 |
67K |
3 |
02/04/20 |
02/04/20 |
ASX - By Stock
|
165
|
67K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Oncosil breakthrough device receives CE Marking approval
|
|
DrDopamine
|
165 |
67K |
4 |
01/04/20 |
01/04/20 |
ASX - By Stock
|
165
|
67K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: FDA Grants Breakthrough Device Designation
|
|
DrDopamine
|
31 |
13K |
2 |
20/03/20 |
20/03/20 |
ASX - By Stock
|
31
|
13K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: FDA Grants Breakthrough Device Designation
|
|
DrDopamine
|
31 |
13K |
6 |
19/03/20 |
19/03/20 |
ASX - By Stock
|
31
|
13K
|
6
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
DrDopamine
|
395 |
273K |
14 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
395
|
273K
|
14
|
|
ASX - By Stock
|
OSL |
Re:
Ann: CE Mark Update
|
|
DrDopamine
|
395 |
273K |
3 |
25/02/20 |
25/02/20 |
ASX - By Stock
|
395
|
273K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Stabilised and primed to go higher
|
|
DrDopamine
|
109 |
93K |
7 |
16/02/20 |
16/02/20 |
ASX - By Stock
|
109
|
93K
|
7
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron to Test its Compounds Against Coronavirus
|
|
DrDopamine
|
1.0K |
704K |
3 |
16/02/20 |
16/02/20 |
ASX - By Stock
|
1.0K
|
704K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Stabilised and primed to go higher
|
|
DrDopamine
|
109 |
93K |
2 |
15/02/20 |
15/02/20 |
ASX - By Stock
|
109
|
93K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
OSL Chart
|
|
DrDopamine
|
114 |
78K |
5 |
13/02/20 |
13/02/20 |
ASX - By Stock
|
114
|
78K
|
5
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron to Test its Compounds Against Coronavirus
|
|
DrDopamine
|
1.0K |
704K |
0 |
10/02/20 |
10/02/20 |
ASX - By Stock
|
1.0K
|
704K
|
0
|
|